1. Ray’s Q2 2025 Earnings Analysis: What Caused the Shock?

Ray recorded consolidated revenue of KRW 27.5 billion, an operating loss of KRW 1.8 billion, and a net loss of KRW 3.6 billion in Q2 2025. These figures fell significantly short of market expectations, with operating profit swinging to a loss from a KRW 0.2 billion profit in Q1. The main cause of the decline in sales is attributed to sluggish performance in both domestic and export markets for their digital diagnostic systems. External factors such as the global economic slowdown, intensified competition, and increased exchange rate volatility also appear to have contributed to the poor performance.

2. Ray’s Fundamental Analysis: Crisis or Opportunity?

Ray is currently experiencing deteriorating fundamentals, including declining sales, continued operating losses, and a high debt-to-equity ratio. However, the company’s commitment to securing future growth engines through R&D investment, amounting to 10.7% of sales, in areas such as digital therapeutic solutions and 3D printing systems, is a positive sign. Whether the results of these new businesses can translate into improved profitability will be a key factor determining Ray’s future growth.

3. Ray Investment Strategy: Is It Time to Invest?

Caution is advised for investing in Ray at this time. In the short term, downward pressure on the stock price is expected due to the earnings shock. In the medium to long term, careful monitoring of profitability improvement, new business performance, and financial structure improvement is necessary. Continuous attention should also be paid to risk factors such as exchange rate volatility, interest rate burdens, and intensified competition. It is advisable to wait until positive changes are confirmed, such as an earnings turnaround, tangible results from new businesses, and improvement in financial structure.